Pharmaceutical intermediates are a kind of fine chemical products in the production process from pharmaceutical chemical raw materials to raw materials or pharmaceuticals. The synthesis of chemical drugs depends on high-quality pharmaceutical intermediates. This kind of chemical product does not require a drug production license, and can be produced in ordinary chemical factories. As long as it reaches a certain level, it can be used in the synthesis of drugs. my country needs more than 2,000 kinds of raw materials and intermediates for chemical industry every year, with a demand of more than 2.5 million tons. After years of development, the chemical raw materials and intermediates required for my country's pharmaceutical production can basically be matched, and only a small part needs to be imported. And because our country is relatively rich in resources and the price of raw materials is low, many intermediates have been exported in large quantities.

　　How to divide pharmaceutical intermediate products?

　　There are many types of pharmaceutical intermediates, which can be divided into antibiotic drug intermediates, antipyretic and analgesic pharmaceutical intermediates, cardiovascular system pharmaceutical intermediates, anticancer pharmaceutical intermediates and other major categories according to the application field. There are many types of specific pharmaceutical intermediates, such as imidazole, furan, phenolic intermediates, aromatic hydrocarbon intermediates, pyrrole, pyridine, biochemical reagents, sulfur-containing, nitrogen-containing, halogen compounds, heterocyclic compounds, starch, mannitol , microcrystalline cellulose, lactose, dextrin, ethylene glycol, powdered sugar, inorganic salts, ethanol intermediates, stearate, amino acids, ethanolamines, potassium salts, sodium salts and other intermediates, etc. wait.

　　In addition, in recent years, due to the increasingly stringent drug regulatory requirements, increasing difficulty in drug research and development, and rising prices, multinational pharmaceutical companies have maintained good quality throughout the life cycle of drugs in order to shorten the time to market for patented drugs and reduce R&D and production costs. Profit space, improve its own operating efficiency, gradually transform from a "vertical integration" business model to a "development cooperation" business model, professionally decompose the research, development, production and other business links of patented drugs, and outsource them to pharmaceutical contract research companies, Pharmaceutical custom R&D and production enterprises and other professional institutions, that is, pharmaceutical custom R&D and production (CMO)